Edward Garmey, MD
Chief Medical Officer
Edward Garmey, M.D. is an oncology drug development consultant affiliated with Alacrita Consulting, LLC. (London, U.K.) and based in Cambridge, MA. Dr. Garmey is currently the Chief Medical Officer at H3 Biomedicine, a clinical-stage biopharmaceutical company in Cambridge, MA. that leverages cancer genomics and real-life patient data to advance its projects to clinical proof of concept. Other companies for which Dr. Garmey has consulted include Bicycle Therapeutics (Cambridge, U.K.)(CMO); Cielo Therapeutics (Westborough, MA.); Ex Cubio Pharmaceuticals (Lexington, MA.); Genocea Biosciences (Cambridge, MA.); NED Biosystems (Waltham, MA.)(CMO); Raze Therapeutics (Cambridge, MA.); TargImmune Therapeutics AG (Basel, CH); and X4 Pharmaceuticals (Cambridge, MA.)(CMO). Prior to his transition to consulting, Dr. Garmey served for five years as Chief Medical Officer and Senior Vice President at Cerulean Pharma, Inc., a clinical-stage oncology company based in Cambridge, MA. focused on the design and development of nanopharmaceutical-drug-conjugates differentially directed to cancer cells. Under his tenure at Cerulean, the company completed a successful IPO (NASDAQ:CERU) in April, 2014, and its clinical group, while increasing in size from one to 12 employees including three oncologist M.D.s, launched eight clinical trials and brought its second experimental drug into the clinic. A pediatric hematologist-oncologist by training, Dr. Garmey is a graduate of Harvard and New York Universities and completed his medical training at the Mount Sinai Medical Center (N.Y.); the Children’s Hospital of Los Angeles; and the Memorial Sloan-Kettering Cancer Center (N.Y.). Dr. Garmey completed additional research fellowships at the National Institutes of Health (1998-99) and Botswana-Harvard Partnership for H.I.V. Research in Gaborone, Botswana (1999-2000) and he is a recipient of young investigators awards from the American Society of Hematology and the American Heart Association. Dr. Garmey has presented at numerous international conferences and is an author on over 50 peer-reviewed abstracts and manuscripts. In 2009, he was appointed as a medical consultant to the New York City Investment Fund’s $1.25 Million “BioAccelerate NYC Prize” for biomedical research. Additionally, in 2011, he was appointed by Eric Lander to the scientific advisory board of the Harvard-MIT Broad Institute’s Cancer Vaccine Initiative. Dr. Garmey resides near Boston, Massachusetts, where he serves as an adjunct instructor at Harvard Medical School’s Therapeutics Graduate Program and additionally as a member of the Boards of Overseers at the Beth Israel Deaconess Medical Center and The Trustees of Reservations.